Lilly Targets Aduhelm With Aggressive Plans For Donanemab In Alzheimer’s

 
• By Joseph Haas
target
Lilly has Biogen in its sights for Alzheimer's disease competition • Source: Alamy (hoch2wo / Alamy Stock Photo/Alamy Stock Photo)

More from Earnings

More from Business